Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed sentiment. While financial discipline and a strong cash position are positives, the net loss and lack of specific guidance on certain programs create uncertainty. The Q&A section highlights management's confidence in safety profiles and potential synergies, but also reveals avoidance of specific numerical guidance and partnership details. The market cap suggests moderate reaction, leading to a neutral prediction for the stock price movement.
Key Financial Performance
Cash, cash equivalents, and marketable securities $217.6 million as of June 30, 2025. This figure supports operations into 2027, well beyond upcoming clinical milestones.
Total net loss $52.7 million for Q2 2025, compared to $58.7 million for the same period in 2024. This represents a decrease primarily due to a reduction in stock-based compensation, personnel-related expenses, and clinical trial costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NMRA-215 prioritization: Prioritized obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor. This decision is based on evidence supporting the role of centrally-acting drugs in driving weight loss and the potential of NLRP3 inhibition to improve upon current obesity treatments.
Pipeline breadth: Neumora expects up to 6 clinical data readouts in the next 18 months, showcasing the potential impact of its pipeline.
NMRA-861 Phase I study: Initiated Phase I study of NMRA-861, a highly potent and selective M4 Positive Allosteric Modulator (PAM), targeting schizophrenia with potential for improved efficacy and tolerability.
Obesity market opportunity: Obesity affects over 2.5 billion people globally, with projections to reach 4 billion by 2035. Current treatments have limitations, and Neumora aims to address this unmet need with NMRA-215.
Schizophrenia treatment market: Schizophrenia treatments face challenges like suboptimal efficacy and side effects. NMRA-861 aims to provide a more favorable therapeutic profile.
Financial position: Ended Q2 2025 with $217.6 million in cash, cash equivalents, and marketable securities, supporting operations into 2027.
Cost management: Net loss decreased to $52.7 million in Q2 2025 from $58.7 million in Q2 2024, driven by reduced stock-based compensation, personnel expenses, and clinical trial costs.
Pipeline prioritization: Focused resources on programs with the highest potential impact, such as NMRA-215 for obesity and NMRA-861 for schizophrenia, while discontinuing less promising programs.
R&D event: Plans to host an R&D event in Q4 2025 to provide detailed updates on its programs and strategies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Obesity Treatment Challenges: Current obesity treatments face significant challenges, including up to one-third of patients being nonresponders, high rates of discontinuation (68% within one year), and common adverse effects such as gastrointestinal issues. Weight regain after discontinuation is also prevalent.
Pipeline Prioritization Risks: The company is focusing resources on prioritized programs, which may lead to delays or discontinuation of other programs, potentially impacting the breadth of their pipeline and future opportunities.
Schizophrenia Treatment Limitations: Current schizophrenia treatments are limited by suboptimal efficacy, side effects, and high rates of non-adherence, posing challenges for the development of new therapies like NMRA-861.
Financial Sustainability: While the company has a cash runway into 2027, its net loss for the quarter was $52.7 million, highlighting ongoing financial pressures that could impact long-term sustainability.
Regulatory and Clinical Risks: The success of clinical programs depends on achieving positive outcomes in ongoing and future trials, which are inherently uncertain and subject to regulatory scrutiny.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Obesity as lead indication for NMRA-215: Neumora has prioritized obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor. Clinical studies for NMRA-215 are expected to begin in Q1 2026, with preclinical data to be shared in fall 2025.
Pipeline updates and clinical milestones: Neumora expects up to 6 clinical data readouts in the next 18 months. Key milestones include Phase Ib data for NMRA-511 in Alzheimer's disease agitation by year-end 2025, Phase III KOASTAL program data for navacaprant in major depressive disorder in Q1 2026, and Phase I data for NMRA-861 in Q1 2026. Another M4 PAM, NMRA-898, is expected to enter the clinic in 2025.
R&D event and strategic focus: Neumora plans to host an R&D event in Q4 2025 to provide detailed updates on its programs. The company is focused on advancing programs with substantial unmet needs and significant market opportunities.
Schizophrenia treatment with NMRA-861: Phase I trials for NMRA-861, a selective M4 Positive Allosteric Modulator (PAM), are ongoing. Data on safety, tolerability, and pharmacokinetics are expected in Q1 2026. Another PAM is expected to enter clinical trials in 2025.
Financial outlook: Neumora has $217.6 million in cash and anticipates its cash runway to support operations into 2027, covering all upcoming clinical milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the preclinical study design in obesity, the type of diet, whether you're looking to combine GLP-1s, and what sort of comparator arms you're looking to implement in the study? Are there any aspects of weight loss you're looking to demonstrate, such as better quality weight loss or maintenance of weight loss post-GLP-1 withdrawal?
A:The study for NMRA-215, an NLRP3 inhibitor, will involve a diet-induced obesity study in mice. The goals include assessing NMRA-215 as a monotherapy for obesity, testing it in combination with semaglutide (a standard GLP-1), and evaluating its potential as a maintenance treatment post-GLP-1 withdrawal. The aim is to demonstrate incretin-like weight loss with better tolerability and cost-effectiveness.
Q:Could you provide more description on what gives you confidence that NMRA-861 would be safer than the 266 molecule, which was also from the Vanderbilt deal?
A:NMRA-861 and NMRA-898 are structurally distinct from 266. Preclinical studies in rabbits showed no convulsions at doses and exposures exceeding those of 266, which had unexpected convulsions. This structural distinction and safety data provide confidence in NMRA-861's safety profile.
Q:Can you provide any color on screen failure rates for the KOASTAL program studies or parameters that might give you confidence in site quality? Also, can you comment on the male-to-female ratio enrolled so far?
A:The KOASTAL program has implemented enhanced medical monitoring, verified clinical trials, and reduced the number of participating sites to improve site quality. More females than males have been enrolled, aligning with the prevalence of MDD. Specific ratios were not disclosed.
Q:What should we expect from the NMRA-511 data, and what would be considered good for you to move forward?
A:The NMRA-511 Phase Ib study is signal-seeking and not powered for statistical significance. Part A showed good tolerability in healthy elderly participants. Part B will evaluate safety, tolerability, and efficacy in AD agitation, with the primary endpoint being the change in CMAI score. The data will guide further clinical development.
Q:What are your thoughts on developing NMRA-215 in obesity, given the competitive space and the costs involved? Would you consider partnering at a certain stage?
A:Neumora is committed to advancing NMRA-215 in obesity due to its distinct mechanism and CNS penetration. The program is included in the company's operating plan and cash runway through 2027. No specific comments were made on potential partnerships.
Q:Are you expecting efficacy in the preclinical model for NMRA-215 to be greater than 15% weight loss in a monotherapy setting? Has your confidence in KOASTAL-2 or 3 changed after seeing VENTURA 1 and 2 trial data?
A:NMRA-215 is expected to show compelling weight loss in the DIO model, potentially comparable to or exceeding competitors' 10-15% weight loss. Confidence in KOASTAL-2 and 3 remains unchanged, supported by differences in pharmacology and program design compared to other trials.
Q:Could you give us any color on preclinical work for NMRA-861 that gives you confidence around its safety profile?
A:Preclinical studies in rabbits showed no convulsions at doses and exposures exceeding those of 266. This data, along with the molecule's distinct structure, supports confidence in NMRA-861's safety profile.
Q:What synergies do you see between your existing neuro-focused pipeline and obesity? How did you decide that this is the right next indication for Neumora? Can you reconcile what your cash runway includes in terms of R&D initiatives?
A:Neumora sees synergies in developing centrally-acting drugs for obesity, aligning with its expertise in CNS mechanisms. The decision was based on growing evidence of central mechanisms in obesity treatment. The cash runway of $217 million supports all critical programs, including NMRA-215, through 2027.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical expectations for NMRA-215's weight loss efficacy in the DIO model and did not comment on potential partnerships for the obesity program. Additionally, they did not disclose specific male-to-female enrollment ratios for the KOASTAL program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Berns
Blue
Chief Operationg
Chief Scientific
Corporate Participant
DIO
Development officer
GLP
KOASTAL
LLC Research
Operationg Development
Phase Ib
Phase NMRA
RD
Research Division
Scientific Officer
activity efficacy
afternoon
ascending dose
brain penetrant
breakthrough
disease approach
health challenge
inhibition
medication
milestone
model
obesity
study NMRA
treatment option
use
weight loss
world
NMRA Transcript
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Positive3-30
The earnings call revealed strong financial performance, with a 25% revenue increase, a shift from net loss to net income, and improved operating margins. These positive financial metrics, despite the lack of strategic or operational updates, suggest a favorable stock price movement. The market cap indicates a potential strong reaction, but the absence of strategic guidance tempers expectations to a positive rather than strong positive outlook.
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents a mixed sentiment. While financial discipline and a strong cash position are positives, the net loss and lack of specific guidance on certain programs create uncertainty. The Q&A section highlights management's confidence in safety profiles and potential synergies, but also reveals avoidance of specific numerical guidance and partnership details. The market cap suggests moderate reaction, leading to a neutral prediction for the stock price movement.
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call reveals mixed signals: strong financial positioning with cash runway into 2027 is positive, but increased net loss and debt facility raise concerns. Clinical trial risks, competitive pressures, and economic factors add uncertainty. The Q&A section highlights confidence in ongoing trials but lacks clarity on certain aspects, which may worry investors. The market cap suggests moderate volatility, but without clear positive catalysts, the stock price is likely to remain stable within a neutral range.
Earnings call transcript: Neumora Therapeutics Q4 2024 beats EPS expectations
Unknown3-3
The earnings call reveals several concerning factors: a failed Phase III trial for navacaprant, regulatory scrutiny, and financial constraints despite reduced operating expenses. Management's vague responses in the Q&A further amplify uncertainty. Although the company maintains a strong cash position, the competitive market, clinical trial risks, and lack of guidance adjustments suggest potential negative sentiment. Given the small-cap nature of the stock, these issues are likely to result in a stock price decline in the short term.
NMRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
